{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Appierto V"],"pubmed_abstract":["<h4>Background</h4>Loco-regional recurrence (LRR) poses a clinical challenge for the follow-up of patients treated with curative intent for early-stage breast cancer (EBC). While circulating tumor DNA (ctDNA) has been shown to predict distant metastases, its value for LRR is less characterized.<h4>Methods</h4>Starting from an index case with documented LRR and available tumor and plasma samples, we report the analysis of the prospective phase III fenretinide prevention trial, which primarily aimed to assess the incidence of second malignancy in women with T1-T2 N0 EBC. Patients were eligible if they had FFPE and/or frozen tissue from primary or recurrent invasive tumor for next generation sequencing, and at least three serial plasma samples for ctDNA analysis by digital PCR.<h4>Results</h4"],"journal":["Frontiers in oncology"],"pagination":["1621322"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12460102"],"repository":["biostudies-literature"],"pubmed_title":["Circulating tumor DNA to anticipate loco-regional recurrence in early-stage breast cancer: a proof-of-concept study."],"pmcid":["PMC12460102"],"pubmed_authors":["Cavadini E","Tamborini E","Manitto R","Busico A","De Marco C","De Santis MC","Folli S","Tiberio P","Silvestri M","Pruneri G","Di Cosimo S","Vingiani A","Appierto V","Scaperrotta G","De Cecco L"],"additional_accession":[]},"is_claimable":false,"name":"Circulating tumor DNA to anticipate loco-regional recurrence in early-stage breast cancer: a proof-of-concept study.","description":"<h4>Background</h4>Loco-regional recurrence (LRR) poses a clinical challenge for the follow-up of patients treated with curative intent for early-stage breast cancer (EBC). While circulating tumor DNA (ctDNA) has been shown to predict distant metastases, its value for LRR is less characterized.<h4>Methods</h4>Starting from an index case with documented LRR and available tumor and plasma samples, we report the analysis of the prospective phase III fenretinide prevention trial, which primarily aimed to assess the incidence of second malignancy in women with T1-T2 N0 EBC. Patients were eligible if they had FFPE and/or frozen tissue from primary or recurrent invasive tumor for next generation sequencing, and at least three serial plasma samples for ctDNA analysis by digital PCR.<h4>Results</h4","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-03T22:44:39.853Z","creation":"2026-05-31T03:06:30.577Z"},"accession":"S-EPMC12460102","cross_references":{"pubmed":["41018107"],"doi":["10.3389/fonc.2025.1621322"]}}